As such, currently both WHO-HAEM5 and ICC strongly recommend screening all LBCLs with FISH analysis for MYC, BCL2 and BCL6 in order to identify more aggressive subsets of LBCLs requiring dose-intense treatment protocols, which are usually adopted in fit and young patients. This evidence concerns the gene BCL6 and intrahepatic cholangiocarcinoma.